|
Re: Opportunity continues to knock
|
|
Resverlogix Corp.
|
Aug 13, 2024 07:50AM
|
|
Re: OTC Trading questions
|
1
|
Zenith Epigenetics
|
Mar 03, 2022 09:55AM
|
|
Re: Partnership?
|
3
|
Resverlogix Corp.
|
Jun 22, 2020 06:37PM
|
|
Re: Patient Enrollment Modeling
|
2
|
Resverlogix Corp.
|
Dec 08, 2018 12:43AM
|
|
Re: Phase 3 - Fall Start
|
1
|
Resverlogix Corp.
|
Jun 22, 2015 11:21AM
|
|
Re: PNAS
|
2
|
Resverlogix Corp.
|
Jan 02, 2021 11:03AM
|
|
Re: put in a bid for 5k more - got 1500 so far
|
2
|
Resverlogix Corp.
|
Jan 29, 2021 12:07PM
|
|
Re: put this question to the zen board
|
1
|
Resverlogix Corp.
|
May 31, 2022 03:52PM
|
|
Re: put this question to the zen board
|
4
|
Resverlogix Corp.
|
May 31, 2022 05:00PM
|
|
Re: Q1- March 31, 2022 on SEDAR
|
5
|
Resverlogix Corp.
|
May 22, 2022 08:45PM
|
|
Re: Questions/comments sent to IR/Chris for Don to review & answer …
|
2
|
Resverlogix Corp.
|
Jul 29, 2024 07:24PM
|
|
Re: Questrade
|
|
Zenith Epigenetics
|
Jan 07, 2024 06:30PM
|
|
Re: Questrade
|
1
|
Zenith Epigenetics
|
Jan 05, 2024 12:41PM
|
|
Re: Questrade
|
2
|
Zenith Epigenetics
|
Jan 05, 2024 11:25PM
|
|
Re: Received a reply too...
|
1
|
Resverlogix Corp.
|
Sep 12, 2017 02:30PM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Aug 29, 2023 06:49PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 10:08AM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
2
|
Resverlogix Corp.
|
Oct 04, 2023 01:49PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
3
|
Resverlogix Corp.
|
Jun 22, 2020 06:21PM
|
|
Re: Resverlogix warrants to be delisted June 21
|
1
|
Resverlogix Corp.
|
Jun 14, 2021 03:07PM
|
